Since BCL2 inhibitors could occupy BH2 and BH3 positions and on the other hand according to our molecular docking analysis, carvacrol and thymol could interact with BCL2 in BH3 and BH1 positions, they may inhibit BCL2 to lead cancer cells to apoptosis pathway45. The gene discussed is BCL2; the disease is cancer.